Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network
Authors' conclusion
COVID-19 vaccination was associated with a reduced risk of hyperthyroidism and an increased risk of hypothyroidism, highlighting the need for ongoing thyroid function monitoring.
Study context
- Population
- Individuals in the TriNetX database, January 1, 2022, to December 31, 2023propensity-score matched
- Participants
- 1,166,748 vs 1,166,748
- Exposure
- COVID-19 vaccination vs no vaccination
- Vaccinatedn = 1,166,748
- Unvaccinatedn = 1,166,748reference
- Outcome
- New diagnoses of subacute thyroiditis, hyperthyroidism and hypothyroidism
Methodological detailspropensity-score matched, TriNetX database
- Propensity-score matched
- TriNetX database
Main finding
As reported in the abstract
New diagnoses of subacute thyroiditis, hyperthyroidism and hypothyroidism, vaccinated vs unvaccinated
Hyperthyroidism risk significantly reduced 3 to 9 months postvaccination, HRs (all 95% CIs below 1)
0.65-0.89
Hyperthyroidism at 12 months, not significant: HR
0.99
95% CI 0.92–1.06
Hypothyroidism risk significantly increased 6 to 12 months postvaccination, HR (all 95% CIs above 1)
1.14-1.30
Observational data: associations, not effects.
Further findings
Hyperthyroidism and hypothyroidism in mRNA vaccine recipients · 12 months
- Risk of both significantly elevated, HR
- 1.16-2.13
Original publication
Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network. J Clin Endocrinol Metab. Published 30 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →